Guardant Health, Inc. (GH)
| Market Cap | 12.15B |
| Revenue (ttm) | 297.89M |
| Net Income (ttm) | -335.71M |
| Shares Out | 101.12M |
| EPS (ttm) | -3.39 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 13 |
| Last Price | $110.80 |
| Previous Close | $113.93 |
| Change ($) | -3.13 |
| Change (%) | -2.75% |
| Day's Open | 117.27 |
| Day's Range | 108.03 - 117.64 |
| Day's Volume | 812,220 |
| 52-Week Range | 74.31 - 181.07 |
Guardant Health (NASDAQ:GH) has observed the following analyst ratings within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 1 0 0 1 Somewhat Bullish 1 0 0 2 Indifferent 0 ...
CareDx just posted 76% year-over-year revenue growth for the first quarter and raised its 2021 guidance.
Guardant Health (GH) delivered earnings and revenue surprises of 40.24% and 5.85%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vas...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announces the appointment of Craig Eagle, MD as the company's new Chief Medical Officer (...
Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming BofA Securities 2021 He...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH) today announced a strategic collaboration with Daiichi Sankyo, Inc. (Daiichi Sankyo) to pursue regulatory approval and commercia...
Their liquid biopsies are giving doctors new and better tools to spot, track, and treat cancers.
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2021 after market ...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, presents new data at the AACR Virtual Annual Meeting I, ...
Bear of the Day: Guardant Health (GH)
The company's newest product received a key approval in New York.
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH) announced that the New York State Department of Health Clinical Laboratory Evaluation Program (CLEP) has approved the Guardant R...
Which healthcare company is a better play for the next decade?
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH) announced that the Centers for Medicare & Medicaid Services (CMS) has approved Advanced Diagnostic Laboratory Test (ADLT) status...
HTHT, FNLPF, GMRE, THRY, and GH have been added to the Zacks Rank #5 (Strong Sell) List on March 29, 2021
This liquid biopsy pioneer is going after a huge potential market.
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, is joining forces with leading patient advocacy groups to expand the Clear Your View init...
Innovation is risky, and these companies are all in.
The diagnostic testing company's growth may be slowing, but this shareholder isn't worried.
The overall stock market sell-off pulled Guardant Health's shares down.
This under-the-radar diagnostics company is thriving yet reasonably priced.
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH) has CE-marked Guardant360® CDx for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), in patients wi...
The company reported disappointing Q4 results.
The company beat revenue expectations, but its bottom-line performance and 2021 outlook weren't what investors hoped for.
Shares of Guardant Health (NASDAQ:GH) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 248.15% over the past year to ($0.94), which miss...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vas...
On Wednesday, February 24, Guardant Health (NASDAQ:GH) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.
These two companies have exciting long-term prospects.
This cannabis producer and liquid biopsy pioneer should make investors a lot of money.
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following virtual investor confe...
Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced the availability of Guardant Reveal™, the first blood-only liquid biopsy test f...
Here's why they're such great picks.
If you screen the market for stocks that have a current ratio higher than 2 and more working capital than long-term debt, as Benjamin Graham, the pioneer of value investing, recommended, the chances tha...
Each of them has clear potential catalysts ahead.
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 202...
Don't get caught chasing the hype.
Patience is a virtue that should prove valuable with these stocks.
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH). Despite guideline recommendations for comprehensive genomic profiling (CGP) of all patients with advanced non-small cell lung c...
Here's how they'll do it.
BARCELONA, Spain & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Vall d'Hebron Institute of Oncology (VHIO), one of Europe's leadin...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, will present data highlighting the clinical utility of G...
And they could do it sooner rather than later.
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming 39th Annual J.P. Morgan...
As is the case every year, the major Wall Street firms we cover here at 24/7 Wall St.
All three could be huge winners in the new year -- and over the long run.
All three have already made investors a lot of money this year.
About GH
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the e... [Read more...]
| Industry Diagnostics & Research | IPO Date Oct 4, 2018 |
| Stock Exchange NASDAQ | Ticker Symbol GH |
Financial Performance
In 2020, GH's revenue was $286.73 million, an increase of 33.75% compared to the previous year's $214.38 million. Losses were -$253.78 million, 235.5% more than in 2019.
Analyst Forecasts
According to 11 analysts, the average rating for GH stock is "Strong Buy." The 12-month stock price forecast is 178.30, which is an increase of 60.92% from the latest price.